Equity Profile
Pre-Earnings Brief
Kimberly-Clark Corporation (KMB) is a leading company in the consumer staples sector, specializing in household products like tissues, diapers, and personal care items. With a market cap of $32 billion, its performance is closely tied to consumer spending trends and demand for essential goods.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and is closely watched by investors.
Revenue Growth
Revenue growth reflects the company's ability to increase sales, which is crucial for sustaining profitability.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
88%
Avg EPS Surprise
+16.96%
Avg Stock Reaction
-0.72%
In Q1 2026, Kimberly-Clark reported an EPS of $1.60, missing estimates by 16.8%. The stock saw a slight increase of 0.19% the following day.
Management Promises & Guidance
Overall, expectations for Kimberly-Clark's upcoming earnings are cautious, especially after a significant EPS miss last quarter. Investors will be looking for signs of recovery in profitability and sales.
Bull Case
If Kimberly-Clark can demonstrate improved cost management and a rebound in sales, it could lead to a positive market reaction and renewed investor confidence.
Bear Case
Conversely, if the company continues to struggle with profitability and fails to provide clear guidance, it may face further stock price declines.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and is closely watched by investors.
Revenue Growth
N/ARevenue growth reflects the company's ability to increase sales, which is crucial for sustaining profitability.
Market Share in Key Segments
N/AUnderstanding market share helps gauge competitive positioning and consumer preference.
Expectations
The print will turn on these two things.
Q1
What is the EPS forecast for the upcoming quarter?
Given the significant miss last quarter, investors will be closely monitoring EPS to gauge recovery.
Q2
How is Kimberly-Clark addressing cost pressures?
With rising costs affecting margins, insights into cost management strategies will be crucial for future profitability.
Edge
Why consensus could be wrong
The Street may underestimate Kimberly-Clark's ability to manage costs effectively, leading to a stronger-than-expected EPS.
Supporting Evidence
The company has a history of beating EPS estimates, with an 88% success rate over the last eight quarters.
Options pricing indicates a significant move, suggesting that the market is bracing for surprises, either positive or negative.
Key Risk
If EPS exceeds $1.80, it could challenge the current cautious sentiment.
Edge
Pre-commit to what would confirm each case.
The upcoming earnings report is critical for assessing whether Kimberly-Clark can rebound from recent performance issues.
Bull Confirmed If
A positive EPS of $1.80 or higher would confirm the bull case and suggest a recovery in profitability.
Bear Confirmed If
An EPS below $1.50 would reinforce the bear case and raise concerns about ongoing challenges.
Pre-Earnings Positioning
Implied Move
±11.31%
Historical Avg
±2.7%
The options market is pricing in a significant move of over 11%, indicating heightened uncertainty ahead of the earnings report.
Options are pricing ±11.3% while KMB has averaged ±2.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
24.6%
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Kimberly-Clark beats expectations, history suggests the stock could rise by around 2.99% on the first day.
In-Line / Cautious
If results are in line but cautious, the stock may experience a muted reaction as investors assess future guidance.
Miss
A miss could lead to a decline, with historical patterns showing an average drop of around 0.19% after misses.
Preparation
House & Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
Net selling
Recent Transactions
Traded Nov 12, 2025 · disclosed Dec 15, 2025
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Summit Therapeutics Inc.